A Study to Investigate RO7200220 in Participants With Uveitic Macular Edema (Meerkat)
Uveitic Macular Edema
About this trial
This is an interventional treatment trial for Uveitic Macular Edema
Eligibility Criteria
Inclusion Criteria: Female participants: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined by the protocol Diagnosis of macular edema associated with non-infectious uveitis (NIU) Diagnosis of active or inactive, acute, or chronic NIU of any etiology and of any anatomical type (anterior, intermediate, posterior, panuveitis) BCVA letter score of 73 to 19 letters (inclusive) on Early Treatment Diabetic Retinopathy Study (EDTRS)-like charts Exclusion Criteria: Evidence of active or latent syphilis infection Evidence of active or latent tuberculosis infection and/or positive tuberculosis assay, or previous or current HIV diagnosis Serious acute or chronic medical or psychiatric illness History of major ocular and non-ocular surgical procedures Uncontrolled IOP or glaucoma or chronic hypotony Any anatomical changes or media opacity in the study eye preventing evaluation of retina, vitreous, and capture of study images Prior use of IVT biologics including anti-VEGFs less than 2-4 months prior to Day 1; received IVT Methotrexate within 4 months prior to Day 1 Prior macular laser therapy, cataract surgery within 6 months and laser capsulotomy within 3 months of Day 1 Topical corticosteroids and/or topical NSAID > 3 drops per day in the 14 days prior to Day 1 (D1); intraocular or periocular corticosteroid injections in the 2 months prior to D1; subconjunctival corticosteroid injection within 1 month prior to Day 1; an OZURDEX implant in the 4 months prior to D1; YUTIQ, RETISERT or ILUVIEN implant in the 3 years prior to D1 Diagnosis of macular edema due to any cause other than NIU Any major ocular conditions that may require medical or surgical intervention during the study period to prevent vision loss
Sites / Locations
- Kaiser Permanente Southern CaliforniaRecruiting
- Colorado Retina Associates, PC
- Retina Vitreous Associates of FloridaRecruiting
- Cumberland Valley Retina PCRecruiting
- VitreoRetinal Surgery, PLLC.; DBA Retina Consultants of MinnesotaRecruiting
- Truhlsen Eye InstituteRecruiting
- Envision Ocular, LLCRecruiting
- The Retina ConsultantsRecruiting
- Wake Forest Baptist Health Eye CentreRecruiting
- The Ohio State University Investigational Drug ServicesRecruiting
- Oregon Health & Science UniRecruiting
- Erie Retinal SurgeryRecruiting
- Palmetto Retina CenterRecruiting
- Tennessee Retina PCRecruiting
- Vanderbilt Eye InstituteRecruiting
- Austin Clinical Research LLCRecruiting
- Texas Retina AssociatesRecruiting
- Wagner Kapoor InstituteRecruiting
- Spokane Eye Clinical ResearchRecruiting
- LKH-Univ.Klinikum Graz; Universitäts-AugenklinikRecruiting
- Medizinische Universität Wien; Universitätsklinik für Augenheilkunde und OptometrieRecruiting
- Alberta Retina ConsultantsRecruiting
- Ivey Eye InstituteRecruiting
- Kensington Vision and Research CentreRecruiting
- McGill University Health CenterRecruiting
- CHU de Quebec-Universite LavalRecruiting
- Peking Union Medical College HospitalRecruiting
- Beijing Tongren HospitalRecruiting
- The Second Hospital of Jilin University; ophthalmology departmentRecruiting
- The First Affiliated Hospital, Chongqing Medical UniversityRecruiting
- Second Affiliated Hospital Zhejiang University College of Medicine; OphthalmologyRecruiting
- Shanghai First People's HospitalRecruiting
- Tianjin Medical University Eye HospitalRecruiting
- Ren Min Hospital Affiliated Wu Han UniversityRecruiting
- Wuxi No.2 People's HospitalRecruiting
- Rambam Medical Center; OpthalmologyRecruiting
- Hadassah MC; OphtalmologyRecruiting
- Meir Medical Center; OphtalmologyRecruiting
- Rabin MC; OphtalmologyRecruiting
- Kaplan Medical Center; OphtalmologyRecruiting
- Tel Aviv Sourasky MC; OphtalmologyRecruiting
- AUSL ? IRCCS Santa Maria Nuova; Immunologia OculareRecruiting
- Irccs Ospedale San Raffaele;U.O. OculisticaRecruiting
- ASST FATEBENEFRATELLI SACCO; Oculistica (Sacco)Recruiting
- Pusan National University HospitalRecruiting
- Yeungnam University Medical CenterRecruiting
- Ajou University Medical CenterRecruiting
- Seoul National University Bundang HospitalRecruiting
- Severance Hospital, Yonsei University Health SystemRecruiting
- Asan Medical CenterRecruiting
- Samsung Medical CenterRecruiting
- Seoul St Mary's HospitalRecruiting
- Kim's Eye HospitalRecruiting
- Hospital de la Ceguera APECRecruiting
- Instituto de Oftalmologia Monterrey - Vision100 (IOM)Recruiting
- Het Oogziekenhuis RotterdamRecruiting
- OFTALMIKA Sp. z o.oRecruiting
- Gabinet Okulistyczny Prof Edward WylegalaRecruiting
- SP ZOZ Szpital Uniwersytecki w Krakowie Oddzia? Kliniczny Okulistyki i Onkologii OkulistycznejRecruiting
- SPSK nr 1 w Lublinie; Klinika Chirurgii Siatkowki i Ciala SzklistegoRecruiting
- SPEKTRUM Osrodek Okulistyki KlinicznejRecruiting
- AIBILI - Association for Innovation and Biomedical Research on LightRecruiting
- Instituto de Oftalmologia Dr. Gama PintoRecruiting
- Hospital de Santa Maria; Servico de OftalmologiaRecruiting
- Taipei Veterans General Hospital; OphthalmologyRecruiting
- Mackay Memorial Hospital; OphthalmologyRecruiting
- Chang Gung Medical Foundation - Linkou; Ophthalmology
- Bradford Royal InfirmaryRecruiting
- University Hospital of WalesRecruiting
- Gloucestershire Hospitals NHS Foundation TrustRecruiting
- Moorfields Eye Hospital NHS Foundation TrustRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Sham Comparator
Arm A
Arm B
Arm C
Participants will receive 4 low-dose RO7200220 intravitreal (IVT) injections every 4 weeks (Q4W) to Week 12, followed by as-needed (PRN) dosing from Week 20 to Week 48.
Participants will receive 4 high-dose RO7200220 IVT injections Q4W to Week 12, followed by PRN dosing from Week 20 to Week 48.
Participants will receive 4 sham injections Q4W to Week 12, followed by PRN sham dosing from Week 20 to Week 48.